Details of Disease

General Information of Disease (ID: DIS6FM27)

• Disease Name: Fibrosis
• Disease Class: GA14-GC01: Fibrosis
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DIS6FM27: Fibrosis
• ICD Code:
  ICD-11: ICD-11: GA14-GC01
  ICD-10: ICD-10: L90.5
  ICD-9: ICD-9: 709.2
  Expand ICD-9: 709.2
• Disease Identifiers:
  MONDO ID: MONDO_0032651
  MESH ID: D005355
  UMLS CUI: C4748939
  OMIM ID: 618278
  MedGen ID: 1648312
  SNOMED CT ID: 112674009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Lisuride	DMCME17	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 10 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
EXC 001	DM4FBUH	Phase 2	Antisense drug	[2]
GKT-137831	DMOVB3Y	Phase 2	Small molecular drug	[3]
Nivocasan	DMUX8JZ	Phase 2	NA	[4]
RXI-109	DMXG9ES	Phase 2	Small interfering RNA	[5]
SAR-100842	DMDMQW0	Phase 2	NA	[6]
ChronSeal	DM90BUD	Phase 1/2	NA	[7]
Carmeseal	DMA05KG	Phase 1	NA	[8]
CC-90001	DMHPZFD	Phase 1	NA	[9]
MMI-0100	DMIMVEX	Phase 1	NA	[10]
PXS-25	DMVQJOS	Phase 1	NA	[11]

This Disease is Treated as An Indication in 5 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID28621580-Compound-WO2013112959C68	DM15OKA	Patented	Small molecular drug	[12]
Pyridine and pyrimidine derivative 1	DMGEYJW	Patented	Small molecular drug	[13]
Pyrimidine derivative 5	DMNET19	Patented	Small molecular drug	[12]
Pyrimidine derivative 6	DMBAHYO	Patented	Small molecular drug	[12]
Pyrimidine derivative 7	DMF6DUT	Patented	Small molecular drug	[12]

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
LF-984	DMIYMS2	Terminated	NA	[14]
SM-16	DMHXJV2	Terminated	NA	[15]

This Disease is Treated as An Indication in 16 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABC-3	DMNOM75	Investigative	NA	[8]
ANG-3062	DMHLMFG	Investigative	NA	[8]
ANG-3067	DM9CY9Q	Investigative	NA	[8]
ANG-4011	DMMAOKV	Investigative	NA	[8]
DRP-049	DMBUH02	Investigative	NA	[16]
Fluorofenidone	DMGJCCH	Investigative	Small molecular drug	[8]
FT-011	DMYA4JR	Investigative	NA	[8]
FT-026	DMRI7P4	Investigative	NA	[8]
FT-061	DMORY3L	Investigative	NA	[8]
FT-071	DMT06I7	Investigative	NA	[8]
MGN-4220	DMPIGTT	Investigative	NA	[8]
NCE-401	DMJDBWD	Investigative	NA	[8]
PBI-4419	DM1ZJBJ	Investigative	NA	[8]
Pentraxin 2/analog	DM3LS3M	Investigative	NA	[8]
PRO-GR-300	DMKTSBG	Investigative	NA	[8]
PTL-303	DML0WZ4	Investigative	NA	[8]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 1 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
NHLRC2	OTY4HPWB	Limited	Genetic Variation	[17]

References

• [1] ClinicalTrials.gov (NCT00408915) Continuous Application of Lisuride in Parkinson's Disease by Subcutaneous Infusion. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
• [3] ClinicalTrials.gov (NCT02010242) Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria. U.S. National Institutes of Health.
• [4] Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats. Apoptosis. 2013 Dec;18(12):1481-91.
• [5] ClinicalTrials.gov (NCT02246465) A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT01651143) Proof of Biological Activity of SAR100842 in Systemic Sclerosis. U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT00797706) Phase I/II Dose Ranging CHRONSEAL Study in Venous Leg Ulcers. U.S. National Institutes of Health.
• [8] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [9] ClinicalTrials.gov (NCT02110420) First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001. U.S. National Institutes of Health.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2094).
• [11] Cation-independent mannose 6-phosphate receptor inhibitor (PXS25) inhibits fibrosis in human proximal tubular cells by inhibiting conversion of latent to active TGF-beta1. Am J Physiol Renal Physiol.2011 Jul;301(1):F84-93.
• [12] VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
• [13] Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012957)
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026469)
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1788).
• [17] NHLRC2 variants identified in patients with fibrosis, neurodegeneration, and cerebral angiomatosis (FINCA): characterisation of a novel cerebropulmonary disease.Acta Neuropathol. 2018 May;135(5):727-742. doi: 10.1007/s00401-018-1817-z. Epub 2018 Feb 8.